Towards precision oncology in advanced prostate cancer

SY Ku, ME Gleave, H Beltran - Nature Reviews Urology, 2019 - nature.com
Metastatic biopsy programmes combined with advances in genomic sequencing have
provided new insights into the molecular landscape of castration-resistant prostate cancer …

Current treatment strategies for advanced prostate cancer

K Komura, CJ Sweeney, T Inamoto… - … Journal of Urology, 2018 - Wiley Online Library
During the past decade, treatment strategies for patients with advanced prostate cancer
involving stage IV (T4N0M0, N1M0 or M1) hormone‐sensitive prostate cancer and recurrent …

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

W Abida, A Patnaik, D Campbell, J Shapiro… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic
castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly (ADP …

NCCN guidelines insights: Prostate cancer, version 1.2021: Featured updates to the NCCN guidelines

E Schaeffer, S Srinivas, ES Antonarakis… - Journal of the National …, 2021 - jnccn.org
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a
prostate cancer diagnosis and include management options for localized, regional, and …

[HTML][HTML] Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer

R de Wit, J de Bono, CN Sternberg… - … England Journal of …, 2019 - Mass Medical Soc
Background The efficacy and safety of cabazitaxel, as compared with an androgen-signaling–
targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration …

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label …

DJ Khalaf, M Annala, S Taavitsainen, DL Finch… - The Lancet …, 2019 - thelancet.com
Background Abiraterone acetate plus prednisone and enzalutamide are both used for the
treatment of metastatic castration-resistant prostate cancer. We aimed to determine the best …

[HTML][HTML] Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) …

S Gillessen, A Omlin, G Attard, JS De Bono… - Annals of …, 2015 - Elsevier
ABSTRACT The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC)
Expert Panel identified and reviewed the available evidence for the ten most important areas …

Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology

EM Schaeffer, S Srinivas, N Adra, Y An… - Journal of the National …, 2023 - jnccn.org
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions
regarding the workup of patients with prostate cancer, risk stratification and management of …

Tumor clone dynamics in lethal prostate cancer

S Carreira, A Romanel, J Goodall, E Grist… - Science translational …, 2014 - science.org
It is unclear whether a single clone metastasizes and remains dominant over the course of
lethal prostate cancer. We describe the clonal architectural heterogeneity at different stages …

Treatment of advanced prostate cancer—A review of current therapies and future promise

S Sumanasuriya, J De Bono - Cold Spring …, 2018 - perspectivesinmedicine.cshlp.org
Despite many recent advances in the therapy for metastatic castration-resistant prostate
cancer (mCRPC), the disease remains incurable, although men suffering from this disease …